Drugs

, Volume 76, Issue 14, pp 1349–1364 | Cite as

Androgenetic Alopecia: An Update of Treatment Options

Review Article

Abstract

Androgenetic alopecia (AGA) is characterized by a non-scarring progressive miniaturization of the hair follicle in predisposed men and women with a pattern distribution. Although AGA is a very prevalent condition, approved therapeutic options are limited. This article discusses the current treatment alternatives including their efficacy, safety profile, and quality of evidence. Finasteride and minoxidil for male androgenetic alopecia and minoxidil for female androgenetic alopecia still are the therapeutic options with the highest level evidence. The role of antiandrogens for female patients, the importance of adjuvant therapies, as well as new drugs and procedures are also addressed.

References

  1. 1.
    Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53:708–28.PubMedCrossRefGoogle Scholar
  2. 2.
    Birch MP, Messenger AG. Genetic factors predispose to balding and non-balding in men. Eur J Dermatol. 2001;11:309–14.PubMedGoogle Scholar
  3. 3.
    Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005;10:184–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Lee WS, Lee HJ. Characteristics of androgenetic alopecia in Asian. Ann Dermatol. 2012;24(3):243–52.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Bas Y, Seckin HY, Kalkan G, Takci Z, Citil R, Önder Y, et al. Prevalence and types of androgenetic alopecia in north Anatolian population: a community-based study. J Pak Med Assoc. 2015;65(8):806–9.PubMedGoogle Scholar
  6. 6.
    Küster W, Happle R. The inheritance of common baldness: two B or not two B? J Am Acad Dermatol. 1984;11(5 Pt 1):921–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Yip L, Rufaut N, Sinclair RD. Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol. 2011;52:81–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Olsen EA. Female pattern hair loss. J Am Acad Dermatol. 2001;45:S70–80.I.Google Scholar
  9. 9.
    Ioannides D, Lazaridou E. Female pattern hair loss. Curr Probl Dermatol. 2015;47:45–54.PubMedCrossRefGoogle Scholar
  10. 10.
    Torres F, Tosti A. Female pattern alopecia and telogen effluvium: figuring out diffuse alopecia. Semin Cutan Med Surg. 2015;34(2):67–71.CrossRefPubMedGoogle Scholar
  11. 11.
    Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998;39:578–89.PubMedCrossRefGoogle Scholar
  12. 12.
    Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010;146:1141–50.PubMedCrossRefGoogle Scholar
  13. 13.
    Gupta AK, Charrette A. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatol Treat. 2014;25(2):156–61.CrossRefGoogle Scholar
  14. 14.
    Olsen EA, Whiting DA, Savin R, Rodgers Johnson-Levonas AO, Round E, et al. Global photographic assessment of men aged 18–60 years with male pattern hair loss receiving finasteride 1 mg or placebo. J Am Acad Dermatol. 2012;67(3):379–86.PubMedCrossRefGoogle Scholar
  15. 15.
    Steiner JF. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet. 1996;30(1):16–27.PubMedCrossRefGoogle Scholar
  16. 16.
    Becker CD, Stichtenoth DO, Wichmann MG, Schaefer C, Szinicz L. Blood donors on medication—an approach to minimize drug burden for recipients of blood products and to limit deferral of donors. Transfus Med Hemother. 2009;36(2):107–13.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Propecia [package insert]. White House Station: Merck and Co., Inc.; 2004.Google Scholar
  18. 18.
    Whiting DA, Olsen EA, Savin R, Halper L, Rodgers A, Wang L, et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol. 2003;13:150–60.PubMedGoogle Scholar
  19. 19.
    Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8:1747–53.PubMedCrossRefGoogle Scholar
  20. 20.
    Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2012;9:2927–32.PubMedCrossRefGoogle Scholar
  21. 21.
    Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73:1220–3.PubMedCrossRefGoogle Scholar
  22. 22.
    Belknap SM, Aslam I, Kiguradze T, Temps WH, Yarnold PR, Cashy J, et al. Adverse event reporting in clinical trials of finasteride for androgenic alopecia: a meta-analysis. JAMA Dermatol. 2015;151(6):600–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5alpha-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8:872–84.PubMedCrossRefGoogle Scholar
  24. 24.
    Ali AK, Heran BS, Etminan M. Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: a pharmacovigilance study. Pharmacotherapy. 2015;35(7):687–95.PubMedCrossRefGoogle Scholar
  25. 25.
    Singh MK, Avram M. Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a serious concern or red herring? J Clin Aesthet Dermatol. 2014;7(12):51–5.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol. 1999;141(3):398–405.CrossRefPubMedGoogle Scholar
  27. 27.
    Cash TF. The psychology of hair loss and its implication for patient care. Clin Dermatol. 2001;19(2):161–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Cash TF. Attitudes, behaviors, and expectations of men seeking medical treatment for male pattern hair loss: results of a multinational survey. Curr Med Res Opin. 2009;25(7):1811–20.PubMedCrossRefGoogle Scholar
  29. 29.
    Yamazaki M, Miyakura T, Uchiyama M, Hobo A, Irisawa R, Tsuboi R. Oral finasteride improved quality of life of androgenetic alopecia patients. J Dermatol. 2011;38(8):773–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Mansouri P, Farshi S, Safar F. Finasteride-induced gynecomastia. Indian J Dermatol Venereol Leprol. 2009;75(3):309–10.PubMedCrossRefGoogle Scholar
  31. 31.
    Ramot Y, Czarnowicki T, Zlotogorski A. Finasteride induced gynecomastia: case report and review of the literature. Int J Trichology. 2009;1(1):27–9.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Ferrando J, Grimalt R, Alsina M, Bulla F, Manasievska E. Unilateral gynecomastia induced by treatment with 1 mg of oral finasteride. Arch Dermatol. 2002;138(4):543–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Glina S, Neves PA, Saade R, Netto NR Jr, Soares JB, Galuppo AG. Finasteride-associated male infertility. Rev Hosp Clin Fac Med Sao Paulo. 2004;59(4):203–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Liu KE, Binsaleh S, Lo KC, Jarvi K. Propecia-induced spermatogenic failure: a report of two cases. Fertil Steril. 2008 Sep;90(3):849.e17-9.Google Scholar
  35. 35.
    Chiba K, Yamaguchi K, Li F, Ando M, Fujisawa M. Finasteride-associated male infertility. Fertil Steril. 2011;95(5):1786.e9–11.Google Scholar
  36. 36.
    Overstreet JW, Fuh VL, Gould J, Howard SS, Lieber MM, Hellstrom W, et al. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol. 1999;162(4):1295–300.PubMedCrossRefGoogle Scholar
  37. 37.
    Amory JK, Wang C, Swerdloff RS, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007;92(5):1659–65.PubMedCrossRefGoogle Scholar
  38. 38.
    Samplaski MK, Lo K, Grober E, Jarvi K. Finasteride use in the male infertility population: effects on semen and hormone parameters. Fertil Steril. 2013;100(6):1542–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Pole M, Koren G. Finasteride. Does it affect spermatogenesis and pregnancy? Can Fam Physician. 2001;47:2469–70.PubMedPubMedCentralGoogle Scholar
  40. 40.
    D’Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol. 2007;8:21–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Guess HA, Gormley GJ, Stoner E, Oeserling JE. The effect of finasteride on prostate specific antigen: review of available data. J Urol. 1992;155:3–9.CrossRefGoogle Scholar
  42. 42.
    Oesterling JE, Roy J, Agha A, Shown T, Krarup T, Johansen T, et al. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Urology. 1997;50:13–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–24.PubMedCrossRefGoogle Scholar
  44. 44.
    Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, REDUCE Study Group, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192–202.PubMedCrossRefGoogle Scholar
  45. 45.
    Lynn R, Krunic A. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction? Dermatol Ther. 2010;23:544–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Trüeb RM, Swiss Trichology Study Group. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology. 2004;209:202–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Kohler C, Tschumi K, Bodmer C, Schneiter M, Birkhaeuser M. Effect of finasteride 5 mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecol Endocrinol. 2007;23(3):142–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Stout SM, Stumpf JL. Finasteride treatment of hair loss in women. Ann Pharmacother. 2010;44(6):1090–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot EH. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2014;80:521–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006;142:298–302.PubMedCrossRefGoogle Scholar
  51. 51.
    Price VH, Roberts JL, Hordinsky M, Olsen EA, Savin R, Bergfeld W, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43:768–76.PubMedCrossRefGoogle Scholar
  52. 52.
    Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1 mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc. 1999;4:282–4.PubMedCrossRefGoogle Scholar
  53. 53.
    van Zuuren EJ, Fedorowicz Z, Carter B. Evidence-based treatments for female pattern hair loss: a summary of a Cochrane systematic review. Br J Dermatol. 2012;167:995–1010.PubMedCrossRefGoogle Scholar
  54. 54.
    Yeon JH, Jung JY, Kim BJ, Youn SW, Park KC, et al. 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol. 2011;25(2):211–4.PubMedCrossRefGoogle Scholar
  55. 55.
    Bowman CJ, Barlow NJ, Turner KJ, Wallace DG, Foster PM. Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. Toxicol Sci. 2003;74:393–406.PubMedCrossRefGoogle Scholar
  56. 56.
    Roussouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stafanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.CrossRefGoogle Scholar
  57. 57.
    Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5-alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89:2179–84.PubMedCrossRefGoogle Scholar
  58. 58.
    Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, et al. Dutasteride Alopecia Research Team. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55:1014–23.PubMedCrossRefGoogle Scholar
  59. 59.
    Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63:252–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Harcha WG, Barboza Martínez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, et al. A randomized, active-and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489–98.CrossRefGoogle Scholar
  61. 61.
    Boyapati A, Sinclair R. Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia. Australas J Dermatol. 2013;54(1):49–51.PubMedCrossRefGoogle Scholar
  62. 62.
    Jung JY, Yeon JH, Choi JW, Kwon SH, Kim BJ, Youn SW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol. 2014;53(11):1351–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Roehrborn CG, Boyle P, Nickel JC, Hoefner K. Andriole G; ARIA3001, ARIA3002, and ARIA3003 Study Investigators. Efficacy and safety of dual inhibitor of 5-a-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434–41.PubMedCrossRefGoogle Scholar
  64. 64.
    Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003;44(1):82–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol. 2005;4:637–40.PubMedGoogle Scholar
  66. 66.
    Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2009;75:47–51.PubMedCrossRefGoogle Scholar
  67. 67.
    Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A novel finasteride 0.25 % topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52(10):842–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Caserini M, Radicioni M, Leuratti C, Terraqni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25 % topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016;54(1):19–27.PubMedCrossRefGoogle Scholar
  69. 69.
    Andrasfay A; Intrepid Therapeutics, Inc. A phase 2 study to evaluate the safety and efficacy of CB-03-01 solution, a comparator solution and vehicle solution in males with androgenetic alopecia [ClinicalTrials.gov identifier NCT02279823]. US National Institutes of Health, ClincalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02279823. Accessed 16 Mar 2016.
  70. 70.
    Cassiopea. Breezula™. http://www.cassiopea.com/activities/product-pipeline/breezula.aspx. Accessed 16 Mar 2016.
  71. 71.
    Yip L, Sinclair R. Antiandrogen therapy for androgenetic alopecia. Expert Rev Dermatol. 2006;1(2):261–9.CrossRefGoogle Scholar
  72. 72.
    Shaw JC. Antiandrogen therapy in dermatology. Int J Dermatol. 1996;35(11):770–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol. 1985;112:124–5.PubMedCrossRefGoogle Scholar
  74. 74.
    Camacho-Martínez FM. Hair loss in women. Semin Cutan Med Surg. 2009;28:19–32.PubMedCrossRefGoogle Scholar
  75. 75.
    Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin. 2010;28(3):611–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152:466–73.PubMedCrossRefGoogle Scholar
  77. 77.
    Plovanich M, Weng QY, Mostaghimi A. Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatol. 2015;151(9):941–4.PubMedCrossRefGoogle Scholar
  78. 78.
    Peereboom-Wynia JD, van der Willigen AH, van Joost T, Stolz E. The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females. Acta Derm Venereol. 1989;69:395–8.PubMedGoogle Scholar
  79. 79.
    Vexiau P, Chaspoux C, Boudou P, et al. Effects of minoxidil 2 % vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol. 2002;146:992–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Blumeyer A, Tosti A, Messenger A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011;9(Suppl 6):S1–57.PubMedCrossRefGoogle Scholar
  81. 81.
    van Zuuren EJ, Fedorowicz Z, Carter B, Andriolo RB, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2012;5:CD007628.PubMedGoogle Scholar
  82. 82.
    Levy LL, Emer JJ. Female pattern alopecia: current perspectives. Int J Womens Health. 2013;29(5):541–56.Google Scholar
  83. 83.
    Paradisi R, Porcu E, Fabbri R, Seracchioli R, Battaglia C, Venturoli S. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother. 2011;45:469–75.PubMedCrossRefGoogle Scholar
  84. 84.
    Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003;79:91–5.PubMedCrossRefGoogle Scholar
  85. 85.
    Yazdabadi A, Sinclair R. Treatment of female pattern hair loss with the androgen receptor antagonist flutamide. Aust J Dermatol. 2011;52:132–4.CrossRefGoogle Scholar
  86. 86.
    Nicole E, Rogers MD, Marc R, Avram MD. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008;59:547–66.CrossRefGoogle Scholar
  87. 87.
    Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6:130–6.CrossRefPubMedGoogle Scholar
  88. 88.
    Kvedar JC, Baden HP, Levine L. Selective inhibition by minoxidil of prostacyclin production by cells in culture. Biochem Pharmacol. 1988;37(5):867–74.PubMedCrossRefGoogle Scholar
  89. 89.
    Michelet JF, Commo S, Billoni N, Mahé YF, Bernard BA. Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol. 1997;108(2):205–9.PubMedCrossRefGoogle Scholar
  90. 90.
    Buhl AE, Waldon DJ, Baker CA, Johnson GA. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol. 1990;95:553–7.PubMedCrossRefGoogle Scholar
  91. 91.
    Buhl AE, Baker CA, Dietz AJ. Minoxidil sulfotransferase activity influences the efficacy of Rogaine topical solution (TS): enzyme studies using scalp and platelets. J Invest Dermatol. 1994;102:534.Google Scholar
  92. 92.
    Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5 % topical minoxidil versus 2 % topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377–85.PubMedCrossRefGoogle Scholar
  93. 93.
    Olsen E, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5 % minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57:767–74.PubMedCrossRefGoogle Scholar
  94. 94.
    Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Bartels NG. A randomized, single-blind trial of 5 % minoxidil foam once daily versus 2 % minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011;65(1126–34):e2.PubMedGoogle Scholar
  95. 95.
    Lucky A, Picquadio D, Ditre C, et al. A randomized, placebo-controlled trial of 5 % and 2 % topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50:541–53.PubMedCrossRefGoogle Scholar
  96. 96.
    Dawber RP, Rundegren J. Hypertrichosis in females applying minoxidil topical solution and in normal controls. J Eur Acad Dermatol Venereol. 2003;17(3):271–5.PubMedCrossRefGoogle Scholar
  97. 97.
    American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pedriatics. 2001;108:776–89.CrossRefGoogle Scholar
  98. 98.
    Sasaki S, Hozumi Y, Kondo S. Influence of prostaglandin F2alpha and its analogues on hair regrowth and follicular melanogenesis in a murine model. Exp Dermatol. 2005;14(5):323–8.PubMedCrossRefGoogle Scholar
  99. 99.
    Tauchi M, Fuchs TA, Kellenberger AJ, Woodward DF, Paus R, Lütjen-Drecoll E. Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost. Br J Dermatol. 2010;162(6):1186–97.PubMedCrossRefGoogle Scholar
  100. 100.
    Blume-Peytavi U, Lonnfors S, Hillmann K, Bartels NG. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1 % on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012;66(5):794–800.PubMedCrossRefGoogle Scholar
  101. 101.
    Khidhir KG, Woodward DF, Farjo NP, Farjo BK, Tang ES, Wang JW, et al. The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias. FASEB J. 2013;27(2):557–67.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    ClinicalTrials.gov. Search results: bimatoprost alopecia. US National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?term=bimatoprost+alopecia&Search=Search. Accessed 2 Feb 2016.
  103. 103.
    Emer JJ, Stevenson ML, Markowitz O. Novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03 % solution. J Drugs Dermatol. 2011;10(7):795–8.PubMedGoogle Scholar
  104. 104.
    Vaccaro M, Barbuzza O, Borgia F, Cannavo SP. Erosive pustular dermatosis of the scalp following topical latanoprost for androgenetic alopecia. Dermatol Ther. 2015;28(2):65–7.PubMedCrossRefGoogle Scholar
  105. 105.
    Garza LA, Liu Y, Yang Z, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012;4(126):126–34.CrossRefGoogle Scholar
  106. 106.
    Nieves A, Garza LA. Does prostaglandin D2 hold the cure to male pattern baldness? Exp Dermatol. 2014;23(4):224–7.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Van Cutsem J, Van Gerven F, Cauwenbergh G, Odds F, Janssen PAJ. The anti-inflammatory effects of ketoconazole. J Am Acad Dermatol. 1991;25:257–61.PubMedCrossRefGoogle Scholar
  108. 108.
    Inui S, Itami S. Reversal of androgenic alopecia by topical ketoconzole: relevance of anti-androgenic activity. J Dermatol Sci. 2007;45:66–8.PubMedCrossRefGoogle Scholar
  109. 109.
    Perez BSH. Ketoconazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Med Hypotheses. 2004;62:112–5.CrossRefGoogle Scholar
  110. 110.
    Sonino N, Scaroni C, Biason A, Boscaro M, Mantero F. Low-dose ketoconazole treatment in hirsute women. J Endocrinol Invest. 1990;13:35–40.PubMedCrossRefGoogle Scholar
  111. 111.
    Mester E, Szende B, Gartner P. The effect of laser beams on the growth of hair in mice. Radiobiol Radiother. 1968;9:621–6.Google Scholar
  112. 112.
    Desai S, Mahmoud B, Bhatia A, Hamzavi IH. Paradoxical hypertrichosis after laser therapy: a review. Dermatol Surg. 2010;36(3):291–8.PubMedCrossRefGoogle Scholar
  113. 113.
    Oron U, Ilic S, DeTaboada L, Streeter J. Ga-As (808-nm) laser irradiation enhances ATP production in human neuronal cells in culture. Photomed Laser Surg. 2007;25:180–2.PubMedCrossRefGoogle Scholar
  114. 114.
    Satino J, Markou M. Hair regrowth and increased hair tensile strength using the HairMax laser comb for low-level laser therapy. Int J Cosmet Surg Aesthet Dermatol. 2003;5(2):113–7.CrossRefGoogle Scholar
  115. 115.
    Leavitt M, Charles G, Heyman E, Michaels D. HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: a randomized, double-blind, sham device-controlled, multicentre trial. Clin Drug Investig. 2009;29(5):283–92.PubMedCrossRefGoogle Scholar
  116. 116.
    Kim H, Woong Choi J, Young Kim J, Won Shin J, Lee S, Huh C. Lowlevel light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device–controlled multicenter trial. Dermatol Surg. 2013;39(8):1177–83.CrossRefPubMedGoogle Scholar
  117. 117.
    Lanzafame RJ, Blanche RR, Bodian AB, Chiacchierini RP, Fernandez-Obregon A, Kazmirek ER. The growth of human scalp hair mediated by visible red light laser and LED sources in males. American Society for Laser Medicine and Surgery Annual Conference; 3–7 Apr 2013; Boston [Poster].Google Scholar
  118. 118.
    Kim WS, Lee HI, Lim YY, Lee SJ, Kim BJ, Kim MN, et al. Fractional photothermolysis laser treatment of male pattern hair loss. Dermatol Surg. 2011;37(1):41–51.PubMedCrossRefGoogle Scholar
  119. 119.
    Lee GY, Lee SJ, Kim WS. The effect of a 1550 nm fractional erbium-glass laser in female pattern hair loss. J Eur Acad Dermatol Venereol. 2011;25(12):1450–4.PubMedCrossRefGoogle Scholar
  120. 120.
    Wu YF, Wang SH, Wu PS, Fan SM, Chiu HY, Tsai TH, et al. Enhancing hair follicle regeneration by nonablative fractional laser: Assessment of irradiation parameters and tissue response. Lasers Surg Med. 2015;47(4):331–41.PubMedCrossRefGoogle Scholar
  121. 121.
    Rose PT. The latest innovations in hair transplantation. Facial Plast Surg. 2011;27:366–77.PubMedCrossRefGoogle Scholar
  122. 122.
    Leavitt M, Perez-Meza D, Rao NA, Barusco M, Kaufman KD, Ziering C. Effects of finasteride (1 mg) on hair transplant. Dermatol Surg. 2003;31(10):1268–76.Google Scholar
  123. 123.
    Avram MR, Cole JP, Gandelman M, Haber R, Knudsen R, Leavitt MT, Roundtable Consensus Meeting of The 9th Annual Meeting of The International Society of Hair Restoration Surgery, et al. The potential role of minoxidil in the hair transplantation setting. Dermatol Surg. 2002;28(10):894–900.PubMedGoogle Scholar
  124. 124.
    Caroli S, Pathomvanich D, Amonpattana K, Kumar A. Current status of hair restoration surgery. Int Surg. 2011;96(4):345–51.PubMedCrossRefGoogle Scholar
  125. 125.
    Chiang YZ, Tosti A, Chaudhry IH, Lyne L, Farjo B, Farjo N, et al. Lichen planopilaris following hair transplantation and face-lift surgery. Br J Dermatol. 2012;166(3):666–670.PubMedCrossRefGoogle Scholar
  126. 126.
    Draelos ZD. Shampoos, conditioners, and camouflage techniques. Dermatol Clin. 2013;31(1):173–8.PubMedCrossRefGoogle Scholar
  127. 127.
    Cossman JP, Ladizinski B, Lee KC. Pigmented concealing powders for the hair loss patient. J Cosmet Dermatol. 2013;12(4):322–4.PubMedCrossRefGoogle Scholar
  128. 128.
    Park JH, Moh JS, Lee SY, You SH. Micropigmentation: camouflaging scalp alopecia and scars in Korean patients. Aesthetic Plast Surg. 2014;38(1):199–204.PubMedCrossRefGoogle Scholar
  129. 129.
    Conde ME, Fernández SME, Suárez FR. Platelet-rich plasma: applications in dermatology. Actas Dermosifiliogr. 2015;106(2):104–11.CrossRefGoogle Scholar
  130. 130.
    Li ZJ, Choi HI, Choi DK, Sohn KC, Im M, Seo YJ, et al. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg. 2012;38(7 Pt 1):1040–6.PubMedCrossRefGoogle Scholar
  131. 131.
    Miao Y, Sun YB, Sun XJ, Du BJ, Jiang JD, Hu ZQ. Promotional effect of platelet-rich plasma on hair follicle reconstitution in vivo. Dermatol Surg. 2013;39(12):1868–76.PubMedCrossRefGoogle Scholar
  132. 132.
    Uebel CO, da Silva JB, Cantarelli D, Martins P. The role of platelet plasma growth factors in male pattern baldness surgery. Plast Reconstr Surg. 2006;118(6):1458–66.PubMedCrossRefGoogle Scholar
  133. 133.
    Perez-Meza D, Leavitt M, Mayer M. The growth factor. Part 1: clinical and histological evaluation of the wound healing and revascularization of the hair graft after the hair transplant surgery. Hair Transpl Forum Int. 2007;17:173–5.Google Scholar
  134. 134.
    Park KY, Kim HK, Kim BJ, Kim MN. Letter: platelet-rich plasma for treating male pattern baldness. Dermatol Surg. 2012;38:2042–4.PubMedCrossRefGoogle Scholar
  135. 135.
    Khatu SS, More YE, Gokhale NR, Chavhan DC, Bendsure N. Platelet-rich plasma in androgenic alopecia: myth or an effective tool? J Cutan Aesthet Surg. 2014;7(2):107–10.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Gkini MA, Kouskoukis AE, Tripsianis G, Rigopoulos D, Kouskoukis K. Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period. J Cutan Aesthet Surg. 2014;7(4):213–9.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Schiavone G, Raskovic D, Greco J, Abeni D. Platelet-rich plasma for androgenetic alopecia: a pilot study. Dermatol Surg. 2014;40(9):1010–9.PubMedCrossRefGoogle Scholar
  138. 138.
    Gentile P, Garcovich S, Bielli A, Scioli MG, Orlandi A, Cervelli V. The effect of platelet-rich plasma in hair regrowth: a randomized placebo-controlled trial. Stem Cells Transl Med. 2015;4(11):1317–23.PubMedCrossRefGoogle Scholar
  139. 139.
    Nusbaum AG, Tosti A. Commentary on a randomized placebo-controlled, double-blind, half-head study to assess the efficacy of platelet-rich plasma on the treatment of androgenetic alopecia. Dermatol Surg. 2016;42(4):498–9.CrossRefPubMedGoogle Scholar
  140. 140.
    Jeong K, Lee YJ, Kim JE, Park YM, Kim BJ, Kang H. Repeated microneedle stimulation induce the enhanced expression of hair-growth-related genes. Int J Trichol. 2012;4:117.Google Scholar
  141. 141.
    Kim BJ, Lim YY, Kim HM, Lee YW, Won CH, Huh CH, et al. Hair follicle regeneration in mice after wounding by microneedle roller. Int J Trichology. 2012;4:117.Google Scholar
  142. 142.
    Dhurat R, Sukesh MS, Avhad G, Dandale A, Pal A, Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichology. 2013;5(1):6–11.PubMedPubMedCentralCrossRefGoogle Scholar
  143. 143.
    Dhurat R, Mathapati S. Response to microneedling treatment in men with androgenetic alopecia who failed to respond to conventional therapy. Indian J Dermatol. 2015;60(3):260–3.PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Chen D, Jarrell A, Guo C, Lang R, Atit R. Dermal β-catenin activity in response to epidermal Wnt ligands is required for fibroblast proliferation and hair follicle initiation. Development. 2012;139:1522–33.PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Reddy S, Andl T, Bagasra A, Lu MM, Epstein DJ, Morrisey EE, et al. Characterization of Wnt gene expression in developing and postnatal hair follicles and identification of Wnt5a as a target of Sonic hedgehog in hair follicle morphogenesis. Mech Dev. 2001;107:69–82.CrossRefPubMedGoogle Scholar
  146. 146.
    Plikus MV, Mayer JA, de la Cruz D, Baker RE, Maini PK, Maxson R, et al. Cyclic dermal BMP signalling regulates stem cell activation during hair regeneration. Nature. 2008;451:340–4.PubMedPubMedCentralCrossRefGoogle Scholar
  147. 147.
    Kishimoto J, Burgeson RE, Morgan BA. Wnt signaling maintains the hair-inducing activity of the dermal papilla. Genes Dev. 2000;14(10):1181–5.PubMedPubMedCentralGoogle Scholar
  148. 148.
    Leirós GJ, Attoresi AI, Balañá ME. Hair follicle stem cell differentiation is inhibited through cross-talk between Wnt/beta-catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia. Br J Dermatol. 2012;166(5):1035–42.PubMedCrossRefGoogle Scholar
  149. 149.
    Follica. Science and technology. http://www.follicabio.com/science-technology/. Accessed 9 Mar 2016.
  150. 150.
    Gurvich N, Klein PS. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther. 2002;96(1):45–66.PubMedCrossRefGoogle Scholar
  151. 151.
    Lee SH, Yoon J, Shin SH, Zahoor M, Kim HJ, Park PJ, et al. Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells. PLoS One. 2012;7(4):e34152.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Jo SJ, Shin H, Park YW, Paik SH, Park WS, Jeong YS, et al. Topical valproic acid increases the hair count in male patients with androgenetic alopecia: a randomized, comparative, clinical feasibility study using phototrichogram analysis. J Dermatol. 2014;41(4):285–91.PubMedCrossRefGoogle Scholar
  153. 153.
    Zimber MP, Ziering C, Zeigler F, Hubka M, Mansbridge JN, Baumgartner M, et al. Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man Phase I clinical trial. J Drugs Dermatol. 2011;10(11):1308–12.PubMedGoogle Scholar
  154. 154.
    Reyes-Cacas TM, Arambulo JT; Histogen. Safety and efficacy of Hair Stimulating Complex (HSC) on hair growth in males with androgenetic alopecia (HSC Phase I/II). [ClinicalTrials.gov identifier NCT01501617]. US National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01501617. Accessed 9 Mar 2016.
  155. 155.
    Yazici Y, Smith SR, Swearingen CJ, Simsek I, DiFrancesco A, Hood JD. Safety and efficacy of a topical treatment (SM04554) for androgenetic alopecia (AGA): results from a phase 1 trial [poster]. In: 9th World Congress for Hair Research; 18–21 Nov 2015; Miami.Google Scholar
  156. 156.
    Yazici Y; Samumed LLC. A phase 2, multicenter, randomized, double-blind, vehicle-controlled study of the safety, tolerability, and efficacy of 0.15 % and 0.25 % concentrations of topical SM04554 solution in male subjects with androgenetic alopecia (AGA) [ClinicalTrials.gov identifier NCT02275351]. ClinicalTrials.gov identifier NCT01501617]. US National Institutes of Health, ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT02275351. Accessed 9 Mar 2016.
  157. 157.
    Toyoshima KE, Asakawa K, Ishibashi N, Toki H, Ogawa M, Hasegawa T, et al. Fully functional hair follicle regeneration through the rearrangement of stem cells and their niches. Nat Commun. 2012;3:784.PubMedPubMedCentralCrossRefGoogle Scholar
  158. 158.
    Adams JU. Raising hairs. Nat Biotechnol. 2011;29(6):474–6.CrossRefPubMedGoogle Scholar
  159. 159.
    RepliCel™. Research findings. http://www.replicel.com/our-science/research-findings/. Accessed 9 Mar 2016.
  160. 160.
    RepliCel™. RepliCel releases positive results from the interim analysis of data from its first-in-man TS001-2009 clinical trial. http://replicel.com/replicel-releases-positive-results-from-the-interim-analysis-of-data-from-its-first-in-man-ts001-2009-clinical-trial/. Accessed 9 Mar 2016.
  161. 161.
    Izadpanah R, Trygg C, Patel B, Kriedt C, Dufour J, Gimble JM, et al. Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J Cell Biochem. 2006;99:1285–97.PubMedPubMedCentralCrossRefGoogle Scholar
  162. 162.
    Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001;107:409–17.PubMedPubMedCentralCrossRefGoogle Scholar
  163. 163.
    Jindo T, Tsuboi R, Takamori K, Ogawa H. Local injection of hepatocyte growth factor/scatter factor (HGF/SF) alters cyclic growth of murine hair follicles. J Invest Dermatol. 1998;110:338–42.PubMedCrossRefGoogle Scholar
  164. 164.
    Weger N, Schlake T. IGF-1 signaling controls the hair growth cycle and the differentiation of hair shafts. J Invest Dermatol. 2005;125:873–82.PubMedCrossRefGoogle Scholar
  165. 165.
    Tomita Y, Akiyama M, Shimizu H. PDGF isoforms induce and maintain anagen phase of murine hair follicles. J Dermatol Sci. 2006;43:105–15.PubMedCrossRefGoogle Scholar
  166. 166.
    Won CH, Yoo HG, Park KY, Shin SH, Park WS, Park PJ, et al. Hair growth-promoting effects of adiponectin in vitro. J Invest Dermatol. 2012;132:2849–51.PubMedCrossRefGoogle Scholar
  167. 167.
    Park BS, Kim WS, Choi JS, Kim HK, Won JH, Ohkubo F, et al. Hair growth stimulated by conditioned medium of adipose-derived stem cells is enhanced by hypoxia: evidence of increased growth factor secretion. Biomed Res. 2010;31:27–34.PubMedCrossRefGoogle Scholar
  168. 168.
    Shin H, Ryu HH, Kwon O, Park BS, Jo SJ. Clinical use of conditioned media of adipose tissue-derived stem cells in female pattern hair loss: a retrospective case series study. Int J Dermatol. 2015;54(6):730–5.PubMedCrossRefGoogle Scholar
  169. 169.
    Fukuoka H, Suga H. Hair regeneration treatment using adipose-derived stem cell conditioned medium: follow-up with trichograms. Eplasty. 2015;26(15):e10.Google Scholar
  170. 170.
    Kerastem. Product pipeline. http://kerastem.com/product-pipeline/. Accessed 16 Mar 2016.
  171. 171.
    Washenik K; Kerastem Technologies, LLC. STYLE—a trial of cell enriched adipose for androgenetic alopecia (STYLE) [ClinicalTrials.gov identifier NCT02275351]. ClinicalTrials.gov identifier NCT01501617]. US National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02503852. Accessed 16 Mar 2016.
  172. 172.
    Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–9.PubMedCentralCrossRefPubMedGoogle Scholar
  173. 173.
    Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv. 2015;1(9):e1500973.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of DermatologyUniversidade de São PauloSão PauloBrazil
  2. 2.Department of DermatologyHospital do Servidor Publico Municipal de São PauloSão PauloBrazil
  3. 3.Department of DermatologyUniversidade Federal do Mato Grosso do SulCampo GrandeBrazil
  4. 4.Department of Dermatology and Cutaneous SurgeryUniversity of Miami Miller School of MedicineMiamiUSA
  5. 5.São PauloBrazil

Personalised recommendations